Pharmacological properties

Interferon alpha 2b recombinant renders to

expressed anti-virus, anti-proliferative and immunomodulatory action. the complex structure of a laferobion causes a number of new effects: in combination with tocopherol acetate and ascorbic acid the anti-virus activity of interferon alpha 2b recombinant increases at 10-14 times, its immunomodulatory action on t - and in - lymphocytes amplifies, immunoglobulin content e is normalized. the antibodies neutralizing anti-virus activity of interferon alpha 2b recombinant, even at use of interferon for 2 years are not formed, functioning of an endogenous system is normalized.

Indication

For children: in complex therapy of acute respiratory viral infections (SARS).

Use

For children: in complex therapy of a SARS the recommended doses make:

to newborn and premature children medicine is appointed on 150,000 ME on 2 suppositories a day with a 12-hour interval. Courses of treatment and breaks between courses — for 5 days.

to Premature newborn children with gestational age less than 34 weeks to appoint medicine on 150,000 ME 3 times a day (in 8 h) rektalno. The course makes 5 days.

to Children aged from 1 year up to 7 years — on 500,000 ME 2 times a day.

to Children at the age of 7–14 years — on 1,000,000 ME 2 times a day within 5 days.

Contraindication

Hypersensitivity to medicine components; presence at the patient of dysfunction of a thyroid gland; presence of heavy visceral violations at patients with Kaposi sarcoma; serious cardiovascular illness; psoriasis; the expressed abnormal liver functions and/or kidneys; epilepsy and other diseases of central nervous system (including functional); chronic hepatitis against the background of the progressing or dekompensirovanny cirrhosis; chronic hepatitis at the patients who are receiving or recently receiving therapy by immunodepressants (except a short course of corticosteroid therapy); autoimmune hepatitis or other autoimmune diseases in the anamnesis. oppression of a myeloid sprout of blood formation.

Side effects

All side reactions connected with application of a laferobion, insignificant or moderately severe, after the end of treatment usually disappear.

General violations: at Laferobion's introduction, grippopodobny symptoms are possible: a fever, fervescence, fatigue, slackness and also a headache, muscle, joints pain, the increased sweating; seldom — vomiting, dizziness, inflows. Emergence of reactions of hypersensitivity to medicament is possible.

Disturbance from the system of blood formation: at prolonged use the leukopenia, thrombocytopenia, anemia, nasal bleedings are possible.

Disturbance from a GIT, a liver: increase in the AlAT and AsAT, SF level, loss of appetite, abnormal liver function.

Endocrine violations: dysfunctions of a thyroid gland.

Disturbance from the central and peripheral nervous system: at prolonged use the dizziness, a sleep disorder, confusion of consciousness, alarming and depressions, hyperexcitability, drowsiness, an ataxy, paresthesias are possible.

Disturbance from a cardiovascular system: AG or arterial hypotension are possible; seldom — tachycardia.

Disturbance from skin and hypodermic fabrics: allergic reactions, including rash (including herpetic), an itch, hyperaemia.

Disturbance from a respiratory system: cough.

Another: changes in the injection site, disorder of vision, renal failure, violation of electrolytic balance.

Special instructions

under observation of the doctor.

At prolonged use of medicine are carried out by control of the general blood test, function of a liver, kidneys and a thyroid gland.

developed analysis of peripheral blood, with an obligatory qualitative and quantitative research of indicators of blood and also biochemical analysis of blood, including determination of content of electrolytes, calcium, liver enzymes and creatinine.

At all patients receiving medicine carefully albumine level in blood plasma and a prothrombin time.

With care to appoint medicine in the presence in the anamnesis of such diseases as diabetes with episodes of ketoacidosis and HOBL, at violations of blood clotting (including thrombophlebitises of a pulmonary artery), at the expressed myelosuppression.

At medicament treatment adequate hydration of an organism; at manifestations of fever it is necessary to exclude other reasons of its emergence. It is recommended to use medicine against the background of antihistaminic and febrifugal therapy.

Development of heavy and medium-weight side effects demands dose adjustment, and in certain cases — treatment cancellations.

in cases: lengthenings of a blood clotting time (at patients with chronic hepatitis), manifestations of a pulmonary syndrome and radiological identification of infiltrate or dysfunction of lungs, emergence or increase in severity of disorders of vision, dysfunction of a thyroid gland (TSH level aberration), decrease in level of albumine in plasma of blood and decrease in a prothrombin time.

At development of reaction of immediate hypersensitivity (urticaria, a Quincke's disease, a bronchospasm, an anaphylaxis) medicine should cancel and take the appropriate measures immediately.

After the termination of an expiration date. Drug is not subject to repeated quality control and extension of an expiration date after its termination.

Use during pregnancy and feeding by a breast. Data on use of medicine during pregnancy and feeding by a breast are absent.

Children. Apply in pediatric practice (see USE).

Ability to influence speed of response at control of vehicles or work with other mechanisms. Some adverse effects from central nervous system caused by use of medicine can affect ability of patients to steer vehicles and to work with potentially dangerous mechanisms.

Interaction

With care should use medicament along with opioid medicines, analgetics, somnolent and sedative (potentially cause myelosuppressive effect).

At simultaneous application with medicines which are metabolized by oxidation (including with xanthine derivatives — Aminophyllinum and theophylline) should consider a possibility of influence of Laferobion on oxidizing metabolic processes. Concentration of theophylline in blood plasma needs to be controlled and if necessary — to adjust the dosing mode.

At use of medicine in a combination with chemotherapeutic medicines (Cytarabinum, doxorubicine, tenipozid, cyclophosphamide) risk of development of life-threatening toxic effects (their weights and duration) increases.

At simultaneous application with a zidovudine the risk of development of a neutropenia increases.

Overdose

did not describe medicine overdose cases laferobion So far. however, as well as at overdose of any medicine, symptomatic therapy with monitoring of functions of vitals and careful observation of a condition of the patient is recommended.

Storage conditions

In original packing for protection against effect of light at a temperature of 2-8 °C.